Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Its first approved product, Casgevy, was developed in collaboration with narrow-moat Vertex Pharmaceuticals to treat transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD). Crispr ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –– Tebapivat Phase 1 ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the third quarter 2024 and ...

Q3 2024 Earnings Call Transcript October 31, 2024 Operator: Good morning, and welcome to Agios’ Third Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today’s call is being ...

Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET. Company Participants. Chris Taylor - Vice President, Investor Relations and ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

Prescribed beta-blockers lower heart rate. “Natural beta-blockers” in common foods, herbs, and supplements may also lower blood pressure. Here are 11 of them. Some foods, herbs, and supplement ...

You can try out the beta version of Apple's generative AI with an iPhone 15 Pro or any iPad or Mac with an M1 chip or later. Here's everything to know about Apple ...

even in iOS 18.2. Apple has also released the first macOS Sequoia 15.2 developer beta with new Apple Intelligence tools as well, 9to5Mac reports. Genmoji apparently isn’t included in that beta.